Five Prime Therapeutics: Annual Report 2014 (Five Prime Therap) - Mar 25, 2015 - Anticipated patent expiry for composition of matter in US in 2026; Anticipated patent expiry for methods of use in US in 2031; Anticipated patent expiry for composition of matter in Japan in 2026; Anticipated patent expiry for composition of matter and methods of use in Europe, Hong Kong, Australia and New Zealand in 2026; Anticipated expiry of exclusively licensed patents in US for composition of matter and methods of producing FP-1039 between 2019 and 2020; Anticipated expiry of additional patents for composition of matter and methods of use in US and ex-US between 2026 and 2034; Anticipated expiry of additional patents for composition of matter and methods of use in EU between 2026 and 2034; Anticipated expiry of additional patents for composition of matter and methods of use in Canada between 2026 and 2034
Anticipated patent expiry • Oncology
|